参考文献/References:
[1] G?man MA,Cozma MA,Dobric? EC ,et al. Dyslipidemia:a trigger for coronary heart disease in Romanian patients with diabetes[J]. Metabolites,2020,10(5):195.
[2] Li Y,Zhao L,Yu D,et al. The prevalence and risk factors of dyslipidemia in different diabetic progression stages among middle-aged and elderly populations in China[J]. PLoS One,2018,13(10):e0205709.
[3] Nelson AJ,Nicholls SJ. Treating dyslipidemia in type 2 diabetes[J]. Cardiol Clin,2018,36(2):233-239.
[4] Gonna H,Ray KK. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes[J]. Diabetes Obes Metab,2019,21 Suppl 1:6-16.
[5] Inaku KO,Ogunkeye OO,Abbiyesuku FM,et al. Elevation of small,dense low density lipoprotein cholesterol—A possible antecedent of atherogenic lipoprotein phenotype in type 2 diabetes patients in Jos,North-Central Nigeria[J]. BMC Clin Pathol,2017,17:26.
[6] Zhang Y, Xu RX, Li S,et al. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease[J]. Nutr Metab Cardiovasc Dis,2015,25(4):426-433.
[7] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2017年版）[J]. 中华糖尿病杂志,2018,10(1):4-67.
[8] Li G,Wu HK,Wu XW,et al. Small dense low density lipoprotein-cholesterol and cholesterol ratios to predict arterial stiffness progression in normotensive subjects over a 5-year period[J]. Lipids Health Dis,2018,17(1):27.
[9] Esteghamati A,Asnafi S,Eslamian M,et al. Associations of small dense low-density lipoprotein and adiponectin with complications of type 2 diabetes[J]. Endocr Res,2015,40(1):14-19.
[10] Shen Y,Chen S,Dai Y,et al. Lipoprotein(a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion[J]. Cardiovasc Diabetol,2019,18(1):82.
[11] European Association for Cardiovascular Prevention & Rehabilitation,Reiner Z, Catapano AL,et al. ESC/EAS Guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology(ESC) and the European Atherosclerosis Society(EAS)[J]. Eur Heart J,2011,32(14):1769-1818.
[12] Diffenderfer MR,Schaefer EJ. The composition and metabolism of large and small LDL[J]. Curr Opin Lipidol,2014,25(3):221-226.
[13] Wu B,Yu Z,Tong T ,et al. Evaluation of small dense low-density lipoprotein concentration for predicting the risk of acute coronary syndrome in Chinese population[J]. J Clin Lab Anal,2020,34(3):e23085.
[14] Berneis KK,Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity[J]. J Lipid Res,2002,43(9):1363-1379.
[15] Krychtiuk KA,Kastl SP,Pfaffenberger S,et al. Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease[J]. PLoS One,2015,10(4):e0123367.
[16] Klisic A,Kavaric N,Vujcic S,et al. Inverse association between serum endocan levels and small LDL and HDL particles in patients with type 2 diabetes mellitus[J]. Eur Rev Med Pharmacol Sci,2020,24(15):8127-8135.
[17] Sakai K,Koba S,Nakamura Y,et al. Small dense low-density lipoprotein cholesterol is a promising biomarker for secondary prevention in older men with stable coronary artery disease[J]. Geriatr Gerontol Int,2018,18(6):965-972.
[18] Izumida T,Nakamura Y,Hino Y,et al. Combined effect of small dense low-density lipoprotein cholesterol (sdLDL-C) and remnant-like particle cholesterol(RLP-C) on Low-grade inflammation[J]. J Atheroscler Thromb,2020,27(4):319-330.
[19] Balling M,Nordestgaard BG,Langsted A,et al. Small dense low-density lipoprotein cholesterol predicts atherosclerotic cardiovascular disease in the Copenhagen general population study[J]. J Am Coll Cardiol,2020,75(22):2873-2875.
[20] Jin JL,Zhang HW,Cao YX,et al. Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes:a prospective,observational cohort study[J]. Cardiovasc Diabetol,2020,19(1):45.
[21] Santos HO,Earnest CP,Tinsley GM,et al. Small dense low-density lipoprotein-cholesterol (sdLDL-C):analysis,effects on cardiovascular endpoints and dietary strategies[J]. Prog Cardiovasc Dis,2020,63(4):503-509.
[22] Jia A,Zeng W,Yu L,et al. Very low-density lipoprotein cholesterol is associated with extent and severity of coronary artery disease in patients with type 2 diabetes mellitus[J]. SAGE Open Med,2019,7:2050312119871786.
[23] Ivanova EA,Myasoedova VA,Melnichenko AA,et al. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases[J]. Oxid Med Cell Longev,2017,2017:1273042.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(5):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(5):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]